Summary

Report Scope
The report provides an overview of the global liquid biopsy with an emphasis on cancer market and analyzes market trends. It includes global revenue ($ million), using 2025 as the base year, estimated data for 2026, and projected data from 2026 through 2031.
The report segments the market by indication, technology, biomarker type, and application. By indication, the study includes lung cancer, breast cancer, colorectal cancer, prostate cancer, and other cancers. By technology, the market is segmented into next-generation sequencing (NGS), polymerase chain reaction (PCR), and other technologies. Based on biomarker type, the report covers circulating nucleic acids, circulating tumor cells (CTCs), exosomes, and circulating proteins. For application, the report includes therapy guidance, therapy monitoring, early cancer screening, and recurrence monitoring. Geographical regions covered in this study include North America (the U.S., Canada, and Mexico), Europe (Germany, the U.K., Italy, France, Spain, and the Rest of Europe), Asia-Pacific (China, Japan, India, South Korea, Australia, and the Rest of Asia-Pacific), the Middle East and Africa (MEA), and South America, with a focus on key countries in these regions.
The report focuses on the key driving trends and challenges shaping the market and vendor landscape. It analyzes and discusses emerging technologies related to the market.
The report concludes by analyzing the competitive landscape and highlighting the leading global liquid biopsy with an emphasis on cancer companies. It also includes a dedicated section on company profiles that covers overviews, key financials, product portfolios, and recent developments for major companies.
Report Includes
- 64 data tables and 58 additional tables
- An up-to-date review and analysis of the global market for liquid biopsy technologies
- Analyses of the global market trends, with sales data for 2023-2025, estimates for 2026, and projections of compound annual growth rates (CAGRs) through 2031
- Evaluation and forecast the overall market size for liquid biopsy technologies and their corresponding market share analysis by indication, technology, biomarker type, clinical application, and region
- Analysis of market opportunities with a review of Porter’s Five Forces model and industry supply chain analysis, considering both micro- and macro environmental factors prevailing in the market
- Explanation of market drivers, restraints and other forces impacting the global market
- Coverage of evolving technologies, the current and future market potential, R&D activities, growth strategies, regulatory framework and reimbursement scenarios, and ESG trends of the market
- Identification of companies best positioned to meet this demand due to their proprietary technologies, mergers and acquisitions, joint ventures and other strategic alliances
- Descriptive profiles of the leading global companies, including Guardant Health, Natera Inc., Exact Sciences Corp., Illumina Inc., and F. Hoffmann-La Roche Ltd.

ページTOPに戻る

Table of Contents

Table of Contents
Chapter 1 Executive Summary
Market Outlook
Scope of Report
Market Summary
Overview
Current Market Scenario
Segmental Analysis
Regional Analysis
Technological Advances
Conclusion
Chapter 2 Market Overview
Overview
Liquid Biopsy Versus Traditional Biopsy
Porter’s Five Forces Analysis in the Liquid Biopsy with Emphasis on the Cancer Market
Potential for New Entrants (Low to Moderate)
Bargaining Power of Suppliers (Moderate to High)
Bargaining Power of Buyers (Moderate)
Threat of Substitutes (Moderate to High)
Competition in the Industry (High)
Macroeconomic Factor Analysis
Cancer Funding
Reimbursement Policy
The U.S. Tariff Scenario
Chapter 3 Market Dynamics
Market Dynamics
Market Drivers
Rising Incidence of Cancer
Growing Awareness of Early Cancer Detection
Advantages of Liquid Biopsy Over Conventional Tissue Biopsy
Market Restraints
Lower Sensitivity of Certain Liquid Biopsy Procedures
Market Opportunities
Rising Significance of Precision Medicine
Growing Oncology Diagnostics Demand in Emerging Markets
Chapter 4 Regulatory Landscape
U.S.
Europe
Other Regions
Chapter 5 Emerging Technologies and Developments
Emerging Technologies
Microfluidics-Based Devices
Nanotechnology
Artificial Intelligence
Clinical Trials Analysis
Key Takeaways
Clinical Trials Analysis, by Type of Study
Clinical Trials Analysis, by Status
Clinical Trials Analysis, by Phase
Patent Analysis
Key Takeaways
Patents, by Year
By Top Applicant
By Top Owner
By Jurisdiction
Chapter 6 Market Segmentation Analysis
Segmentation Breakdown
Market Analysis by Indication
Key Takeaways
Lung Cancer
Breast Cancer
Colorectal Cancer
Prostate Cancer
Other Cancers
Market Analysis by Technology
Key Takeaways
Next-Generation Sequencing (NGS)
Polymerase Chain Reaction (PCR)
Other Technologies
Market Analysis by Biomarker Type
Key Takeaways
Circulating Nucleic Acids
Circulating Tumor Cells (CTCs)
Exosomes
Circulating Protein
Market Analysis by Application
Key Takeaways
Therapy Monitoring
Recurrence Monitoring
Early Cancer Screening
Therapy Guidance
Geographic Breakdown
Market Analysis by Region
Key Takeaways
North America
Europe
Asia-Pacific
South America
Middle East and Africa (MEA)
Chapter 7 Competitive Intelligence
Key Takeaways
Competitive Landscape
Leading Companies in the Liquid Biopsy with Emphasis on Cancer Market
Guardant Health
Natera
Exact Science Corp.
Key Developments and Strategies
Chapter 8 Appendix
Methodology
Sources
Abbreviations
Company Profiles
BIO-RAD LABORATORIES INC.
BIO-TECHNE
DXCOVER LTD
EXACT SCIENCES CORP.
F. HOFFMANN-LA ROCHE LTD.
FREEENOME HOLDINGS INC.
GUARDANT HEALTH INC.
ILLUMINA INC.
MYRIAD GENETICS INC.
NATERA INC.
NEOGENOMICS LABORATORIES
NOVIGENIX AI
PERSONALIS INC.
QIAGEN
THERMO FISHER SCIENTIFIC INC.
List of a Few Emerging Start-ups/ Market Disruptors

ページTOPに戻る

List of Tables/Graphs

List of Tables
Summary Table : Global Market for Liquid Biopsy with Emphasis on Cancer, by Region,Through 2031
Table 1 : Key Liquid Biopsy Modalities
Table 2 : Liquid Biopsy: Major Biomarker
Table 3 : Liquid Biopsy Versus Traditional Biopsy
Table 4 : Porter’s Five Forces Analysis: Overview
Table 5 : Estimated Cancer Incidence, by Region, 2025–2045
Table 6 : Advantages of Liquid Biopsy Over Traditional Tissue Biopsy
Table 7 : Liquid Biopsy Sensitivity, by Cancer, 2025
Table 8 : Other Regions: Liquid Biopsy Regulatory Body
Table 9 : Key Microfluidic Devices for Liquid Biopsy
Table 10 : Clinical Trials in Liquid Biopsy, by Type of Study, March 2026
Table 11 : Clinical Trials in Liquid Biopsy, by Status, March 2026
Table 12 : Clinical Trials in Liquid Biopsy, by Phase, March 2026
Table 13 : Patents, by Top Applicant, 2023–2025
Table 14 : Patents, by Top Owner, 2023–2025
Table 15 : Patents, by Jurisdiction, 2023–2025
Table 16 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 17 : Global Market for Liquid Biopsy with Emphasis on Cancer for Lung Cancer, by Region, Through 2031
Table 18 : Global Market for Liquid Biopsy with Emphasis on Cancer for Breast Cancer, by Region, Through 2031
Table 19 : Global Market for Liquid Biopsy with Emphasis on Cancer for Colorectal Cancer, by Region, Through 2031
Table 20 : Global Market for Liquid Biopsy with Emphasis on Cancer for Prostate Cancer, by Region, Through 2031
Table 21 : Global Market for Liquid Biopsy with Emphasis on Cancer for Other Cancers, by Region, Through 2031
Table 22 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 23 : Global Market for Liquid Biopsy with Emphasis on Cancer for Next-Generation Sequencing , by Region, Through 2031($ Millions)
Table 24 : Global Market for Liquid Biopsy with Emphasis on Cancer for Polymerase Chain Reaction , by Region, Through 2031($ Millions)
Table 25 : Global Market for Liquid Biopsy with Emphasis on Cancer for Other Technologies,by Region, Through 2031
Table 26 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 27 : Circulating Nucleic Acids in Cancer
Table 28 : ctDNA Detection Techniques
Table 29 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Nucleic Acids, by Region, Through 2031
Table 30 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Tumor Cells , by Region, Through 2031($ Millions)
Table 31 : Global Market for Liquid Biopsy with Emphasis on Cancer for Exosomes, by Region, Through 2031
Table 32 : Global Market for Liquid Biopsy with Emphasis on Cancer for Circulating Protein, by Region, Through 2031
Table 33 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 34 : Global Market for Liquid Biopsy with Emphasis on Cancer for Therapy Monitoring, by Region, Through 2031
Table 35 : Global Market for Liquid Biopsy with Emphasis on Cancer for Recurrence Monitoring, by Region, Through 2031
Table 36 : Global Market for Liquid Biopsy with Emphasis on Cancer for Early Cancer Screening, by Region, Through 2031
Table 37 : Global Market for Liquid Biopsy with Emphasis on Cancer for Therapy Guidance, by Region, Through 2031
Table 38 : Global Market for Liquid Biopsy with Emphasis on Cancer, by Region, Through 2031
Table 39 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 40 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 41 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 42 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 43 : North American Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 44 : European Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 45 : European Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 46 : European Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 47 : European Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 48 : European Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 49 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Country, Through 2031
Table 50 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 51 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 52 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 53 : Asia-Pacific Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 54 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 55 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 56 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 57 : South American Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 58 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Indication, Through 2031
Table 59 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Technology, Through 2031
Table 60 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, Through 2031
Table 61 : MEA Market for Liquid Biopsy with Emphasis on Cancer, by Application, Through 2031
Table 62 : Global Market Ranking for Liquid Biopsy with Emphasis on Cancer, 2025
Table 63 : Liquid Biopsy with Emphasis on Cancer: Recent Strategic Developments, 2025–2026
Table 64 : Report Information Sources
Table 65 : Abbreviations Used in the Liquid Biopsy with Emphasis on Cancer Market Report
Table 66 : Bio-Rad Laboratories Inc.: Company Snapshot
Table 67 : Bio-Rad Laboratories Inc.: Financial Performance, FY 2024 and 2025
Table 68 : Bio-Rad Laboratories Inc.: Product Portfolio
Table 69 : Bio-Rad Laboratories Inc.: News/Key Developments, 2024–2025
Table 70 : Bio-Techne: Company Snapshot
Table 71 : Bio-Techne: Financial Performance, FY 2024 and 2025
Table 72 : Bio-Techne: Product Portfolio
Table 73 : Bio-Techne: News/Key Developments, 2024–2025
Table 74 : Dxcover Ltd.: Company Snapshot
Table 75 : Dxcover Ltd.: Product Portfolio
Table 76 : Dxcover Ltd.: News/Key Developments, 2025–2026
Table 77 : Exact Sciences Corp.: Company Snapshot
Table 78 : Exact Sciences Corp.: Product Portfolio
Table 79 : Exact Sciences Corp.: News/Key Developments, 2025
Table 80 : F. Hoffmann-La Roche Ltd.: Company Snapshot
Table 81 : F. Hoffmann-La Roche Ltd.: Financial Performance, FY 2024 and 2025
Table 82 : F. Hoffmann-La Roche Ltd.: Product Portfolio
Table 83 : F. Hoffmann-La Roche Ltd.: News/Key Developments, 2024
Table 84 : Freenome Holdings Inc.: Company Snapshot
Table 85 : Freenome Holdings Inc.: Product Portfolio
Table 86 : Freenome Holdings Inc.: News/Key Developments, 2024–2025
Table 87 : Guardant Health Inc.: Company Snapshot
Table 88 : Guardant Health Inc.: Financial Performance, FY 2024 and 2025
Table 89 : Guardant Health Inc.: Product Portfolio
Table 90 : Guardant Health Inc.: News/Key Developments, 2024–2026
Table 91 : Illumina Inc.: Company Snapshot
Table 92 : Illumina Inc.: Financial Performance, FY 2024 and 2025
Table 93 : Illumina Inc.: Product Portfolio
Table 94 : Illumina Inc.: News/Key Developments, 2024–2025
Table 95 : Myriad Genetics Inc.: Company Snapshot
Table 96 : Myriad Genetics Inc.: Financial Performance, FY 2024 and 2025
Table 97 : Myriad Genetics Inc.: Product Portfolio
Table 98 : Myriad Genetics Inc.: News/Key Developments, 2024-2026
Table 99 : Natera Inc.: Company Snapshot
Table 100 : Natera Inc.: Financial Performance, FY 2024 and 2025
Table 101 : Natera Inc: Product Portfolio
Table 102 : Natera Inc: News/Key Developments, 2025
Table 103 : NeoGenomics Laboratories: Company Snapshot
Table 104 : NeoGenomics Laboratories: Financial Performance, FY 2024 and 2025
Table 105 : NeoGenomics Laboratories: Product Portfolio
Table 106 : NeoGenomics Laboratories: News/Key Developments, 2025–2026
Table 107 : Novigenix AI: Company Snapshot
Table 108 : Novigenix AI: Product Portfolio
Table 109 : Novigenix AI: News/Key Developments, 2024-2026
Table 110 : Personalis Inc.: Company Snapshot
Table 111 : Personalis Inc.: Financial Performance, FY 2024 and 2025
Table 112 : Personalis Inc: Product Portfolio
Table 113 : Personalis Inc.: News/Key Developments, 2024
Table 114 : QIAGEN: Company Snapshot
Table 115 : QIAGEN: Financial Performance, FY 2024 and 2025
Table 116 : QIAGEN: Product Portfolio
Table 117 : QIAGEN: News/Key Developments, 2024–2025
Table 118 : Thermo Fisher Scientific Inc.: Company Snapshot
Table 119 : Thermo Fisher Scientific Inc.: Financial Performance, FY 2024 and 2025
Table 120 : Thermo Fisher Scientific Inc.: Product Portfolio
Table 121 : List of a Few Emerging Start-ups/ Market Disruptors

List of Figures
Summary Figure : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Region, 2025
Figure 1 : Liquid Biopsy: Strengths and Limitations
Figure 2 : Porter’s Five Forces Analysis of the Liquid Biopsy with Emphasis on Cancer Market
Figure 3 : Liquid Biopsy with Emphasis on Cancer: Market Dynamics
Figure 4 : CANCER: Estimated Incidence, 2022–2050
Figure 5 : Emerging Trends/Technologies in the Liquid Biopsy with Emphasis on Cancer Market
Figure 6 : Patents Granted, by Year, 2023–2025
Figure 7 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Indication, 2025
Figure 8 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Technology, 2025
Figure 9 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Biomarker Type, 2025
Figure 10 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Application, 2025
Figure 11 : Global Market Shares of Liquid Biopsy with Emphasis on Cancer, by Region, 2025
Figure 12 : North American Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 13 : European Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 14 : Asia-Pacific Market Shares of Liquid Biopsy with Emphasis on Cancer, by Country, 2025
Figure 15 : Bio-Rad Laboratories Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 16 : Bio-Rad Laboratories Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 17 : Bio-Techne: Revenue Shares, by Business Unit, FY 2025
Figure 18 : Bio-Techne: Revenue Shares, by Country/Region, FY 2025
Figure 19 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Business Unit, FY 2025
Figure 20 : F. Hoffmann-La Roche Ltd.: Revenue Shares, by Country/Region, FY 2025
Figure 21 : Guardant Health Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 22 : Guardant Health Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 23 : Illumina Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 24 : Myriad Genetics Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 25 : Myriad Genetics Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 26 : Natera Inc.: Revenue Shares, by Country/Region, FY 2025
Figure 27 : Personalis Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 28 : QIAGEN: Revenue Shares, by Country/Region, FY 2025
Figure 29 : Thermo Fisher Scientific Inc.: Revenue Shares, by Business Unit, FY 2025
Figure 30 : Thermo Fisher Scientific Inc.: Revenue Shares, by Country/Region, FY 2025